All News
Filter News
Found 47 articles
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
-
Eikon Therapeutics Announces Lease for East Coast Base of Operations in New York City
7/21/2022
Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a lease with Alexandria Real Estate Equities, Inc.
-
Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area
6/16/2022
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters.
-
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
5/16/2022
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
3/31/2022
Eikon Therapeutics Inc. today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
-
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
3/23/2022
Eikon Therapeutics, Inc. today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
-
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team
1/6/2022
Eikon is employing super-resolution microscopy and advanced engineering to invent novel medicines that improve and extend life.
-
BioSpace Announces Top New Biopharma Companies to Watch in 2022
1/5/2022
BioSpace, Inc., the leading life sciences news and careers site, has announced their selections for the industry’s most exciting up-and-coming companies in 2022.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
8/5/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the period ending June 30, 2021.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.